Crown Bioscience

Crown Bioscience

Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research.

Telephone: 0870 166 6234
Address: Hillcrest, Dodgeford Lane, Belton, Loughborough
Postcode: LE12 9TE
Country: United Kingdom
Website: http://www.crownbio.com
Membership type:Corporate 51+ (£1,000+VAT pa)

. With an extensive portfolio of relevant models and predictive tools, CrownBio enables clients to deliver superior clinical candidates.

CrownBio partners with Pierre Fabre to accelerate discovery of immuno-oncology agents

Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces that it has been selected by Pierre Fabre Research Institute as one of their partners to advance their immuno-oncology drug discovery pipeline.

22 June 2018Read in full

CrownBio demonstrates advantages of innovative translational oncology platform

Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, publishes scientific posters with dynamic audio narration.

11 May 2018Read in full

CrownBio launches new humanised target model for immunotherapy

Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, enhances its existing portfolio of humanised drug target models (HuGEMM™) by launching a new transgenic CD3E model to advance development of immuno-oncology (I/O) drugs.

30 April 2018Read in full

Crown Bioscience signs licence agreement with CBT Pharmaceuticals

Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announced today a strategic licensing agreement with CBT Pharmaceuticals (CBT), a US and China-based innovative biopharmaceutical company committed to becoming a leader in the discovery and development of oncology combination therapies.

23 March 2018Read in full

CrownBio enters strategic partnership with Phanes Therapeutics

Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces that it has been selected by Phanes Therapeutics as a strategic partner to advance their oncology drug discovery pipeline.

16 March 2018Read in full

Cambridge Oncology Symposium, Babraham Research Campus

Oncology symposium: Immuno-oncology and next generation targets

The 4th Annual Crown Bioscience Cambridge symposium this year focuses on immuno-oncology and future advances in cancer treatment. Don’t miss out on the chance to hear from AstraZeneca, Janssen, Merus, Kymab, Cantargia, Oxford BioMedica, Crescendo Biologics, and CrownBio, as well as networking with your peers.

15 February 2018Read in full